| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant full-length human protein was used as the immunogen for the SAMD4B antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
SAMD4B Antibody is an antibody targeting SAMD4B. Host: Mouse. Monoclonal. Clone: PCRP-SAMD4B-1H3. Format: Purified. Applications: ELISA, FACS, IF, WB.
Key elements and design rationale
- Target: SAMD4B.
- Immunogen: Recombinant full-length human protein was used as the immunogen for the SAMD4B antibody..
- Species reactivity: Human.
- Localization: Cytoplasm, Nucleus.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Has transcriptional repressor activity. Overexpression inhibits the transcriptional activities of AP-1, p53/TP53 and CDKN1A. [UniProt]
Common research applications
- WB: relative abundance and band pattern assessment using appropriate controls.
- IF/ICC: subcellular localization imaging with proper background controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
